Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.

Key facts

Study ID

NCT01669876

Run by

Rock Creek Pharmaceuticals, Inc.

People needed

85

Starts

2012-08-01

Expected to finish

2015-02-01

Last updated by the study team

2015-04-30

Who can join

Age: 65 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 65 years old.
• Have a diagnosis of probable AD or a concurrent diagnosis of probable AD and possible or probable vascular dementia.
• Score 16 or more on the Mini-Mental State Examination (MMSE).
• Otherwise stable medical history and general health.
• Weigh between 45 kg and 120 kg inclusive.

You may not qualify if…

• Have contra-indications, allergy, or sensitivity to the study products or their components.
• Be currently taking any of the following medications: systemic (oral or injectable) glucocorticoids; interferon-alpha; anti-CD20 antibody (e.g., rituximab); or anti-CTLA-4 antibody (e.g., ipilimumab).
• Be a current smoker or smokeless tobacco user.

Where it is running

• Roskamp Institute — Sarasota, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.